AgeneBio

About:

AgeneBio is a neuroscience pharmaceutical company developing treatments for diseases that impact memory.

Twitter/X: agenebio

Top Investors: National Institutes of Health, National Institute on Aging, Sahsen Ventures, Alzheimer's Drug Discovery Foundation, National Institute of Neurological Disorders and Stroke

Description:

AgeneBio is a neuroscience pharmaceutical company founded by Dr Michela Gallagher in 2008 that is focused on developing treatments for diseases that impact memory. The initial therapeutic targets are Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company is headquartered in Indianapolis but conducts research and development work on a global basis utilizing partner relationships.

Total Funding Amount:

$14.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Carmel, Indiana, United States

Founded Date:

2008-01-01

Contact Email:

gardiner.smith(AT)agenebio.com

Founders:

Michela Gallagher

Number of Employees:

1-10

Last Funding Date:

2019-09-13

IPO Status:

Private

Industries: